Press-release for stocks for AZNCF

Prices are updated after-hours

Fortress Biotech Announces Initiation of Phase 2 Clinical Trial of Triplex for Adults Co-Infected with HIV and CMV
Published: 2021-12-16 (Crawled : 13:30) - globenewswire.com
AZNCF | $140.15 -4.19% 560

| 22.63% | O: 1.5% H: 1.71% C: 1.71%
FBIO | $1.81 2.26% 2.21% 440K

| -31.52% | O: 1.95% H: 0.0% C: -5.34%
AZN | $68.36 -0.25% -0.25% 4M

| 24.23% | O: 2.13% H: 1.9% C: 1.73%
phase 2 trial biotech iot hiv infections

64%

36%

AGBA | $1.02 155.0% 57.94% 120M

ZCMD | $2.86 108.76% 52.1% 2.3M

INVO | $1.555 104.6% 51.13% 5M

ISPC | $0.437 105.16% 49.53% 37M

WLGS | $0.92 84.0% 45.65% 1.6M

OST | $0.499 21.38% 45.26% 1.9M

XPON | $3.1 60.62% 37.74% 17M

TIRX | $0.7 44.39% 30.74% 58M

BNTC | $6.92 44.17% 30.64% 3.5M

GGE | $0.035 19.86% 29.3% 64M

Save your searches and get alerts when important news are released.